Key points are not available for this paper at this time.
Exenatide significantly reduced HbA(1c) in patients with type 2 diabetes failing maximally effective doses of a sulfonylurea. Exenatide was generally well tolerated and was associated with weight loss.
Buse et al. (Mon,) studied this question.